Efficacy, Tolerability and Pharmacokinetics of Subcutaneous Exendin (9-39) in Patients With Post Bariatric Hypoglycemia
Status:
Completed
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the efficacy, safety and pharmacokinetics of subcutaneous
exendin (9-39) in subjects with post-bariatric hypoglycemia. Development of this subcutaneous
formulation of exendin (9-39) would represent a targeted therapeutic approach for this rare
disease with unmet clinical need.